

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-53 (cancelled)

54. (new) A method of treating SARS (Severe Acute Respiratory Syndrome) treatment, comprising administering an effective amount of INDO and its pharmaceutically acceptable salts and derivatives to a subject in need of said treatment thereof.

55. (new) A method of treating hemorrhagic fevers, comprising administering an effective amount of INDO and its pharmaceutically acceptable salts and derivatives to a subject in need of said treatment thereof.

56. (new) The method according to claim 55 wherein fever is caused by Filovirus, Bunyavirus, Arenavirus or Flavivirus.

57. (new) A method of treating viral diseases caused by viruses selected from the group consisting of: Parainfluenza viruses, A, B and C influenza viruses; Respiratory Syncytial Virus; Reovirus; Rotavirus; Coronavirus; Parvovirus; Adenovirus; Papovavirus; Papillomavirus; Poxvirus; and Filovirus, comprising administering an effective amount of INDO and its pharmaceutically acceptable salts and derivatives to a subject in need of said treatment thereof.

58. (new) The method according to claim 54 wherein INDO salts and derivatives comprise alkali metal salts, alkaline

earth metal salts, aluminium salts, zinc salts, ammonium salts, inorganic acid addition salts, and/or organic acid addition salts.

59. (new) The method according to claim 54 wherein said INDO is in the form of a veterinary medicine, agriculture product, or aquaculture product.

60. (new) The method according to claim 54 wherein INDO is administered at concentrations ranging between 10 and 1000 microM.

61. (new) Use according to claim 54, wherein INDO is administered at concentrations ranging between 100 and 400 microM.

62. (new) The method according to claim 54 wherein INDO is administered in combination with pharmaceutically acceptable carriers comprising: preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents and or antioxidants.

63. (new) The method according to claim 54 wherein INDO is administered by the oral, rectal, nasal, topical, vaginal, parenteral routes.

64. (new) The method according to claim 54 wherein INDO is administered in combination with a carrier that is able to penetrate BBB.

65. (new) A pharmaceutical compositions comprising INDO in combination with pharmaceutically effective amounts of at least one compound comprising: Interferon, metals and

corresponding salts and derivatives, prostanoids, antiviral drugs; and corresponding mixtures for the treatment of diseases comprising: tissue cytoprotection, SARS, gastroenteritis, hemorrhagic fevers, respiratory diseases, diseases caused by Coronavirus, Parainfluenza viruses, Influenza viruses, Respiratory Syncytial Virus, virus-caused neoplasias, viral encephalitis, viral diseases in general, and viral diseases caused by genetically modified viruses.

66. (new) The composition according to claim 65 wherein INDO salts and derivatives comprise alkali metal salts, alkaline earth metal salts, aluminium salts, zinc salts, ammonium salts, inorganic acid addition salts, and/or organic acid addition salts.

67. (new) The composition according to claim 65, wherein prostanoids comprise: cyclopentenone prostanoids, PGA_1 , PGA_2 , PGJ_1 , PGJ_2 , $\delta^{12}\text{-PGJ}_2$, and/or 15-deoxy- $\delta^{12,14}\text{-PGJ}_2$.

68. (new) The composition according to claim 65, wherein the metals comprise: zinc, gold, selenium, bismuth and cadmium, or corresponding salts and derivatives.

69. (new) The composition according to claim 65, wherein the metal salts and derivatives comprise: chloride, sulfate, lactate, citrate, iodate, maleate, thiomaleate, diethyl-dithiocarbamate, butyl salicylate, fumarate, succinate, and/or porphyrin tetrakis metachloride.

70. (new) The composition according to claim 65, wherein the metal is Zn and corresponding salts and derivatives comprise: ZnCl_2 , Zn sulfate, Zn lactate, Zn iodate, Zn diethyl-dithiocarbamate, Zn butyl salicylate, and/or Zn porphyrin tetrakis metachloride.

71. (new) The composition according to claim 65, wherein said antiviral drugs comprise: Ribavirin, acyclovir, amantadine, rimantadine, influenza virus neuroaminidase inhibitors, idoxuridine, fosfonacetic acid, AZT, DDC, and/or viral protease inhibitors.

72. (new) The composition according to claim 71, wherein the viral protease inhibitors are HIV protease inhibitors.

73. (new) The composition according to claim 65 wherein INDO is administered in combination with pharmaceutically acceptable carriers comprising: preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents, and/or antioxidants.

74. (new) The composition according to claim 65 wherein INDO is in an oral, rectal, nasal, topical, vaginal, or parenteral form.

75. (new) The composition according to claim 65 wherein INDO in combination with a carrier that is able to penetrate BBB.

76. (new) The composition according to claim 65, further comprising a pharmaceutically acceptable vector.